These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 15674424)
21. Innate immune signaling in the myelodysplastic syndromes. Starczynowski DT; Karsan A Hematol Oncol Clin North Am; 2010 Apr; 24(2):343-59. PubMed ID: 20359630 [TBL] [Abstract][Full Text] [Related]
22. Expression of myeloid differentiation antigens on myeloblasts in bone marrow of patients with myelodysplastic syndromes. Borbenyi Z; Ghosh A; Cinkotai K; Balogh E; Moore M Biomed Pharmacother; 1987; 41(2):101-4. PubMed ID: 3475134 [TBL] [Abstract][Full Text] [Related]
23. [Preliminary study of biological characteristics of myelodysplastic syndromes clonal cells]. Li X; Wu LY; Ying SX; Chang CK; He Q; Song LQ; Pu Q Zhonghua Xue Ye Xue Za Zhi; 2007 Jul; 28(7):478-83. PubMed ID: 18072633 [TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): how can we improve outcomes in the near future? Phillips GL Leuk Res; 2012 Dec; 36(12):1490-5. PubMed ID: 22954609 [TBL] [Abstract][Full Text] [Related]
25. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Kotsianidis I; Bouchliou I; Nakou E; Spanoudakis E; Margaritis D; Christophoridou AV; Anastasiades A; Tsigalou C; Bourikas G; Karadimitris A; Tsatalas C Leukemia; 2009 Mar; 23(3):510-8. PubMed ID: 19020538 [TBL] [Abstract][Full Text] [Related]
26. Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes. Schildgen V; Wulfert M; Gattermann N Exp Hematol; 2011 Jun; 39(6):666-675.e1. PubMed ID: 21447369 [TBL] [Abstract][Full Text] [Related]
27. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells. Draube A; Beyer M; Wolf J Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171 [TBL] [Abstract][Full Text] [Related]
28. Comparison between immunogenotypic findings in de novo AML and AML post MDS. Ohyashiki JH; Ohyashiki K; Kawakubo K; Fujimura T; Shimamoto T; Nakazawa S; Kimura N; Toyama K Leukemia; 1993 Nov; 7(11):1747-51. PubMed ID: 7694003 [TBL] [Abstract][Full Text] [Related]
29. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature. Swolin B; Rödjer S; Westin J Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338 [TBL] [Abstract][Full Text] [Related]
30. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Aggarwal S; van de Loosdrecht AA; Alhan C; Ossenkoppele GJ; Westers TM; Bontkes HJ Br J Haematol; 2011 Jun; 153(5):568-81. PubMed ID: 21488861 [TBL] [Abstract][Full Text] [Related]
31. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758 [TBL] [Abstract][Full Text] [Related]
32. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. Gadji M; Adebayo Awe J; Rodrigues P; Kumar R; Houston DS; Klewes L; Dièye TN; Rego EM; Passetto RF; de Oliveira FM; Mai S Clin Cancer Res; 2012 Jun; 18(12):3293-304. PubMed ID: 22539801 [TBL] [Abstract][Full Text] [Related]
33. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935 [TBL] [Abstract][Full Text] [Related]
34. Acute myeloid leukemia cells fail to activate native human dendritic cells: a potential mechanism of immune evasion. Wehner R; Schumacher P; Bornhäuser M; Ehninger G; Schäkel K; Bachmann M; Schmitz M Leukemia; 2010 Nov; 24(11):1965-7. PubMed ID: 20811402 [No Abstract] [Full Text] [Related]
35. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775 [TBL] [Abstract][Full Text] [Related]
36. Impact of the hypomethylating agent 5-azacytidine on dendritic cells function. Frikeche J; Clavert A; Delaunay J; Brissot E; Grégoire M; Gaugler B; Mohty M Exp Hematol; 2011 Nov; 39(11):1056-63. PubMed ID: 21856273 [TBL] [Abstract][Full Text] [Related]
37. Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation. Bruserud O; Ulvestad E Cell Immunol; 2000 Nov; 206(1):36-50. PubMed ID: 11161436 [TBL] [Abstract][Full Text] [Related]
38. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia. Lübbert M; Mirro J; Kitchingman G; McCormick F; Mertelsmann R; Herrmann F; Koeffler HP Oncogene; 1992 Feb; 7(2):263-8. PubMed ID: 1549347 [TBL] [Abstract][Full Text] [Related]